Reports Q3 revenue $402.1M, consensus $414.31M. “In Q3, we continued to see healthy demand across our portfolio. While revenue was impacted by two supply interruptions, we delivered strong profitability and cash flow through disciplined cost management and operational efficiencies.” said CEO Mojdeh Poul. “We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the company’s transformation.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- IART Upcoming Earnings Report: What to Expect?
- Integra LifeSciences’ Innovative Approach to Ulcer Treatment: A Study Update
- Integra LifeSciences Advances with MIRROR Registry Study on Hematoma Evacuation
- Integra LifeSciences’ Pediatric Study: A Real-World Evaluation of the AERA® Device
- Integra LifeSciences’ New Study on Burn Treatment: What Investors Need to Know